Activating mutations on the EGFR protein, including exon 20 insertion mutations, have a role in NSCLC, but the associated structural changes resulting from the V769insASV and D770insNPG EGFR exon 20 ...
J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...
Through comprehensive genomic and immune analyses, mechanisms of lung cancer resistance after treatment with EGFR inhibition and vaccine therapy were investigated. This case report, together with data ...
The MARIPOSA trial demonstrates that amivantamab plus lazertinib significantly reduces resistance and extends survival in EGFR-mutated NSCLC compared to osimertinib. Dual inhibition of EGFR and MET by ...
MARIPOSA (NCT04487080), which enrolled 1,074 patients, is a randomized, Phase 3 study evaluating RYBREVANT ® in combination with LAZCLUZE™ versus osimertinib and versus LAZCLUZE™ alone in first-line ...
Johnson & Johnson JNJ announced that the FDA granted full approval to its EFGR/MET inhibitor Rybrevant (amivantamab) in non-small cell lung cancer (NSCLC) indication. Following the FDA decision, ...
BARCELONA, Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT ® (amivantamab-vmjw) combined with ...
SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Median overall ...
The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneous therapy for patients with epidermal growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback